Inflammation amplification by Versican: the first mediator.
about
Biological interplay between proteoglycans and their innate immune receptors in inflammationVersican and the regulation of cell phenotype in diseaseVersican and the control of inflammation.A family with Wagner syndrome with uveitis and a new versican mutation.Multimodal Imaging in Wagner Syndrome.The controversial role of retinoic acid in fibrotic diseases: analysis of involved signaling pathways.Knockdown of versican V1 induces a severe inflammatory response in LPS-induced acute lung injury via the TLR2-NF-κB signaling pathway in C57BL/6J mice.Dissection of the human multipotent adult progenitor cell secretome by proteomic analysis.Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.Provisional matrix: A role for versican and hyaluronan.Interplay of extracellular matrix and leukocytes in lung inflammation.Characterizing the "POAGome": A bioinformatics-driven approach to primary open-angle glaucoma.Versican Deficiency Significantly Reduces Lung Inflammatory Response Induced by Polyinosine-Polycytidylic Acid Stimulation.Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer.Glycosaminoglycan and versican deposits in taxane-induced sclerosis.Systems approach to the pharmacological actions of HDAC inhibitors reveals EP300 activities and convergent mechanisms of regulation in diabetes.Versican: a novel modulator of hepatic fibrosis.Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.The role of PSMB9 upregulated by interferon signature in the pathophysiology of cutaneous lesions of dermatomyositis and systemic lupus erythematosus
P2860
Q27005610-3C34E511-5D18-4548-80D0-87EE3009BD06Q27690926-3F2FDCB4-F1C4-4AFB-9A72-623118FE9D13Q33690423-6AFCEBD0-E07F-48E1-A072-6351B75DF84FQ35029339-F95DACFE-D6CC-49F1-B1CA-40542D608C2BQ36057776-D05073FD-1810-430F-95DB-0C18F2270B1CQ36589873-4E5C113B-C956-4DC4-AC2E-C3FD55ED2B95Q36931258-EA02745C-F4A8-4828-84F9-B34DC1590F5FQ37202720-126B0DAE-23F5-4D93-8771-E5DC88F254BCQ38932298-6BE4024C-1F55-4F56-969E-97E6228175CDQ39033619-1FADC77A-43CA-4E1D-8384-7B5BF14A4816Q39080263-1C50BD89-91EE-4373-9659-5EC088212ED1Q39145730-2FF415E2-A721-4A36-AB30-1AEC16ECFAC4Q40432439-69BFF62E-4E56-4C96-98C1-9689ADF3FB49Q47571709-CE7D4125-A630-4C41-9CE1-E0B7ABE348E3Q48187069-591653DF-767F-494C-8775-7D83D1370C1AQ48666421-ECE475E9-1D66-4E5C-B4FF-07069CD10262Q52889712-12972A86-203C-412B-9B79-C8FBD23E309FQ55518010-0D216B0D-5A8C-4117-8075-F4F72EC5DE04Q57719086-63DDB5E7-C24B-4BFB-81AE-CC8309A1CD0C
P2860
Inflammation amplification by Versican: the first mediator.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Inflammation amplification by Versican: the first mediator.
@en
Inflammation amplification by Versican: the first mediator.
@nl
type
label
Inflammation amplification by Versican: the first mediator.
@en
Inflammation amplification by Versican: the first mediator.
@nl
prefLabel
Inflammation amplification by Versican: the first mediator.
@en
Inflammation amplification by Versican: the first mediator.
@nl
P2860
P356
P1476
Inflammation amplification by Versican: the first mediator
@en
P2093
Lianghua Wang
Zhenwei Zhang
P2860
P304
P356
10.3390/IJMS13066873
P407
P50
P577
2012-06-06T00:00:00Z